Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Mon, 6-May 4:01 PM ET)
Blueprint Medicines (BPMC) Gets a Hold from Piper Sandler
TipRanks (Fri, 3-May 8:18 AM ET)
Wells Fargo Remains a Buy on Blueprint Medicines (BPMC)
TipRanks (Fri, 3-May 7:06 AM ET)
Sell/High Risk: Cautious Outlook on Blueprint Medicines Amidst Unsustainable Growth Factors
TipRanks (Fri, 3-May 6:47 AM ET)
Ayvakit’s Sales Surge Supports Buy Rating and Increased Price Target for Blueprint Medicines
TipRanks (Fri, 3-May 6:27 AM ET)
Buy Rating Affirmed for Blueprint Medicines on Strong Financials and Clinical Pipeline Prospects
TipRanks (Fri, 3-May 12:25 AM ET)
Analysts’ Top Healthcare Picks: Bio-Techne (TECH), Gilead Sciences (GILD)
TipRanks (Thu, 2-May 9:41 AM ET)
Blueprint Medicines GAAP EPS of $1.40 beats by $3.05, revenue of $96.12M beats by $14.68M
Seeking Alpha News (Thu, 2-May 7:09 AM ET)
PRNewswire (Thu, 2-May 7:00 AM ET)
Blueprint Medicines Q1 2024 Earnings Preview
Seeking Alpha News (Wed, 1-May 2:30 PM ET)
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Blueprint Medicines trades on the NASDAQ stock market under the symbol BPMC.
As of May 6, 2024, BPMC stock price declined to $106.25 with 784,324 million shares trading.
BPMC has a beta of 1.25, meaning it tends to be more sensitive to market movements. BPMC has a correlation of 0.09 to the broad based SPY ETF.
BPMC has a market cap of $6.65 billion. This is considered a Mid Cap stock.
Last quarter Blueprint Medicines reported $96 million in Revenue and -$1.32 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.34.
In the last 3 years, BPMC stock traded as high as $117.86 and as low as $37.82.
The top ETF exchange traded funds that BPMC belongs to (by Net Assets): VTI, IWM, VB, VXF, XBI.
BPMC has outperformed the market in the last year with a price return of +104.8% while the SPY ETF gained +28.3%. BPMC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +33.5% and +22.3%, respectively, while the SPY returned +4.8% and +4.3%, respectively.
BPMC support price is $103.59 and resistance is $110.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BPMC stock will trade within this expected range on the day.